Tri Locum Partners LP Grows Stake in Korro Bio, Inc. (NASDAQ:KRRO)

Tri Locum Partners LP boosted its holdings in shares of Korro Bio, Inc. (NASDAQ:KRRO - Free Report) by 125.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 144,216 shares of the company's stock after buying an additional 80,202 shares during the quarter. Korro Bio makes up approximately 1.1% of Tri Locum Partners LP's investment portfolio, making the stock its 24th biggest holding. Tri Locum Partners LP owned about 1.54% of Korro Bio worth $5,490,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of KRRO. Marshall Wace LLP bought a new position in shares of Korro Bio during the 4th quarter worth approximately $703,000. Walleye Capital LLC acquired a new position in shares of Korro Bio during the fourth quarter worth $1,570,000. Barclays PLC purchased a new stake in shares of Korro Bio during the 4th quarter valued at $395,000. Raymond James Financial Inc. purchased a new position in Korro Bio during the 4th quarter worth $394,000. Finally, Legal & General Group Plc increased its position in Korro Bio by 664.1% during the 4th quarter. Legal & General Group Plc now owns 4,325 shares of the company's stock valued at $165,000 after buying an additional 3,759 shares in the last quarter. Institutional investors own 13.18% of the company's stock.

Analyst Ratings Changes

KRRO has been the topic of a number of research analyst reports. Oppenheimer began coverage on Korro Bio in a research note on Friday, January 10th. They set an "outperform" rating and a $155.00 price target on the stock. HC Wainwright reissued a "buy" rating and set a $115.00 price objective on shares of Korro Bio in a report on Thursday, March 20th. Cantor Fitzgerald upgraded Korro Bio to a "strong-buy" rating in a research note on Tuesday. Royal Bank of Canada dropped their price target on Korro Bio from $105.00 to $95.00 and set an "outperform" rating on the stock in a research note on Wednesday, March 19th. Finally, Chardan Capital assumed coverage on Korro Bio in a research note on Wednesday, April 16th. They issued a "buy" rating and a $25.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $114.63.

Korro Bio Price Performance

KRRO stock traded up $3.08 during trading on Friday, hitting $21.48. 35,036 shares of the company traded hands, compared to its average volume of 96,143. Korro Bio, Inc. has a 1 year low of $11.13 and a 1 year high of $98.00. The stock's 50-day simple moving average is $18.76 and its 200 day simple moving average is $36.79. The company has a market cap of $201.68 million, a PE ratio of -2.27 and a beta of 2.31.

Korro Bio (NASDAQ:KRRO - Get Free Report) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($2.26) EPS for the quarter, beating the consensus estimate of ($2.33) by $0.07. The firm had revenue of $2.27 million for the quarter. Research analysts expect that Korro Bio, Inc. will post -9.52 earnings per share for the current year.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).